Alere's recent acquisition of Epocal, a provider of best-in-class technologies that support blood gas and electrolyte testing at the point of care.
After working capital and other adjustments made at closing, Alere paid approximately $166 million cash in the acquisition of Epocal, which includes a $15 million payment for the achievement of the first two financial milestones specified in the agreement.
Additional payments of up to $75.5 million could be triggered if milestones linked to the delivery of additional product offerings on the Epocal platform are achieved.
For further deal information visit Current Agreements (subscription required)
Report: Merger and Acquisition Terms and Agreements
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity